




Medtronic

AT500™

DDDRP Pacing System



Prescriber's Package Insert


Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

Front Cover



Part# 182320001

Rev A



1 Description

The Medtronic AT500™ DDDR pacing system is a dual chamber, rate responsive implantable pulse generator (IPG) and is labeled for patients having standard bradycardia indications. The Medtronic AT500™ also contains Atrial Anti-Tachycardia Pacing therapies. In addition, atrial pacing features are provided to further control atrial rates either through increased atrial pacing, rate stabilization, or overdrive pacing post mode switch.

By means of the Model 9465 hand-held telemetry activator, the patient can verify whether the device has detected a suspected atrial arrhythmia and initiate recording of cardiac event data in the device memory.

The Medtronic programmer (Model 9790/C or Model 2090), Model 9968 software, and a telemetry programming head constitute the external portion of the DDDR pacing system. Programmers from other manufacturers are not compatible.

2 Indications

The Medtronic AT500™ system is indicated for the following:

- Rate adaptive pacing in patients who may benefit from increased pacing rates concurrent with increases in activity.
- Accepted patient conditions warranting chronic cardiac pacing which include:
 - Symptomatic paroxysmal or permanent second or third-degree AV block.
 - Symptomatic bilateral bundle branch block.
 - Symptomatic paroxysmal or transient sinus node dysfunctions with or without associated AV conduction disorders.
 - Bradycardia-tachycardia syndrome to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias.

The Medtronic AT500™ system is also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and AV synchrony, which include:

- Various degrees of AV block to maintain the atrial contribution to cardiac output.
- VVI intolerance (e.g., pacemaker syndrome) in the presence of persistent sinus rhythm.

Antitachycardia pacing (ATP) is indicated for termination of atrial tachyarrhythmias in bradycardia patients with one or more of the above pacing indications.

Atrial rhythm management features such as Atrial Rate Stabilization (ARS), Atrial Preference Pacing (APP), and Post Mode Switch Overdrive Pacing (PMOP) are indicated for the suppression of atrial tachyarrhythmias in bradycardia patients with atrial septal lead placement and one or more of the above pacing indications.

3 Contraindications

The Medtronic AT500™ system is contraindicated for:

- Implantation with unipolar pacing leads.
- Concomitant implantation with another bradycardia device.
- Concomitant implantation with an implantable cardioverter defibrillator.

There are no known contraindications for the use of pacing as a therapeutic modality to control heart rate. The patient's age and medical condition, however, may dictate the particular pacing system, mode of operation, and implantation procedure used by the physician.

- Rate responsive modes may be contraindicated in those patients who cannot tolerate pacing rates above the programmed Lower Rate.
- Dual chamber sequential pacing is contraindicated in patients with chronic or persistent supraventricular tachycardias, including atrial fibrillation or flutter.

- Single chamber atrial pacing is contraindicated in patients with an A-V conduction disturbance.
- ATP therapy is contraindicated in patients with an accessory antegrade pathway.

4 Warnings and Precautions

4.1 Sterilization, storage, and device handling

Contents of sterile package – The sterile package contains one implantable Medtronic AT500™ device and one torque wrench.

Temperature limits – Store and transport the package between -18°C (0°F) to 55°C (131°F).

"Use By" date – Do not implant the Medtronic AT500™ device after the "Use by" date, because the battery's longevity could be reduced.

Dropped Device – Do not implant the device if it has been dropped on a hard surface from a height of 30 cm (12 in) or more after removal from its packaging.

Checking and opening the package – Before opening the sterile package tray visually check for any signs of damage that might invalidate the sterility of its contents. Return damaged packages to the manufacturer. For instructions on opening the sterile package, see the diagram inside the lid of the shelf box.

FOR SINGLE USE ONLY. – Do not resterilize or re-implant an explanted Medtronic AT500™ device.

Explant and disposal – Return explanted devices to Medtronic for analysis and disposal. See the back cover for mailing addresses.

Resterilization – Medtronic has sterilized the device package contents with ethylene oxide prior to shipment. Resterilization is necessary only if the seal on the sterile package is broken. (Resterilization does not affect the "Use By" date.) If necessary, reesterilize with ethylene oxide using a validated sterilization process, observing the following precautions:

- Do not reesterilize using an autoclave, gamma radiation, organic cleaning agents (such as alcohol, acetone, etc.), or ultrasonic cleaners.
- Do not reesterilize more than twice.
- Do not exceed 55 °C (131 °F) or 103 kPa (15 psi) when sterilizing.
- Store the reesterilized components for an appropriate period to permit aeration of ethylene oxide gas.

4.2 Lead evaluation and lead connection

Connector compatibility – Do not use any lead with this pacemaker without first verifying connector compatibility. Using incompatible leads can damage the connector or result in a leaking or intermittent connection.

Hex wrench – Do not use a hex wrench with a blue handle or a right-angle hex wrench. These wrenches have torque capabilities greater than is designed for the lead connector.

4.3 Device operation

Fixed bipolar operation – Use of unipolar leads will result in loss of pacing output and sensing.

Rate responsive modes – Do not use rate responsive modes in those patients who cannot tolerate pacing rates above the programmed Lower Rate.

Single chamber atrial modes – Do not use single chamber atrial modes in patients with impaired AV nodal conduction because ventricular capture cannot be assured.

Pacing and sensing safety margins – Consider lead maturation when choosing pacing amplitudes, pacing pulse widths, and sensing levels.

Shipping values – Do not use shipping values for pacing amplitude and sensitivity without verifying that they provide adequate safety margins for the patient.

Electrical reset – Electrical reset is indicated by a programmer warning message displayed immediately upon interrogation. To restore the pacemaker to its previous operation it must be reset and reprogrammed.

Crosstalk – Crosstalk occurs in dual chamber pacemakers when atrial pacing output pulses are sensed by the ventricular lead. Crosstalk results in self-inhibition and is more likely to occur at high sensor-driven pacing rates, high atrial amplitudes, and wide atrial pulse widths. To prevent self-inhibition caused by crosstalk, program Ventricular Safety Pacing (VSP) on.

Slow retrograde conduction – Slow retrograde conduction, especially with conduction time greater than 400 ms, may induce pacemaker-mediated tachycardia (PMT).

Use of a magnet – Positioning a magnet or the programming head over the implanted Medtronic AT500™ device suspends detection and treatment of atrial tachyarrhythmias. The magnet does not alter bradycardia therapy or initiate a Threshold Margin Test.

End of life (EOL) – Replace the Medtronic AT500™ device when the programmer displays an ERI or EOL message, and a battery voltage of 2.60 volts or less.

Oversensing during telemetry – Telemetry communication with the device may cause inappropriate sensed events, resulting in a brief inhibition of bradycardia therapy. Removing the programming head restores the device to normal operation.

Telemetry – Exposure to EMI may briefly interrupt programming and/or telemetry operations. Any successful interrogation or programming verifies proper communication between device and programmer.

Testing for cross-stimulation – At implant and when atrial ATP therapy is enabled, conduct regular testing at the programmed ATP output settings to ensure that ventricular capture does not occur. This is particularly important when the lead is placed in the inferior atrium.

Anti-coagulation – Use of the pacemaker should not change the application of established anti-coagulation protocols.

Rate control – Decisions regarding rate controls should not be based on the ability of the pacemaker to prevent atrial arrhythmias.

4.4 Pacemaker-dependent patients

Diagnostic modes – Never program diagnostic modes (ODO) for pacemaker-dependent patients. For such patients, use the programmer's Inhibit function for brief interruption of outputs.

Inhibit function – Exercise caution when using the programmer to inhibit pacing (for example, to obtain an EGM of the patient's intrinsic activity) because the patient is without pacing support when the Inhibit function is in use.

Ventricular Safety Pacing (VSP) – Always program VSP on for pacemaker-dependent patients.

4.5 Medical therapy hazards

Diathermy – People with metal implants such as pacemakers, implantable cardioverter defibrillators (ICDs), and accompanying leads should not receive diathermy treatment. The interaction between the implant and diathermy can cause tissue damage, fibrillation, or damage to the device components, which could result in serious injury, loss of therapy, and/or the need to reprogram or replace the device.

Electrosurgical cautery – Electrosurgical cautery could induce ventricular arrhythmias and/or fibrillation, or may cause device malfunction or damage. If electrocautery cannot be avoided, observe the following precautions:

- Use a bipolar electrocautery system, where possible.
- Have temporary pacing and defibrillation equipment available.
- Program the device to the DOO mode.
- Use short, intermittent, and irregular bursts at the lowest feasible energy levels.
- Avoid direct contact with the device or leads. If monopolar cautery is used, position the ground plate so that the current pathway does not pass through or near the device system.

External defibrillation – External defibrillation may damage the device or may result in temporary and/or permanent myocardial damage at the electrode tissue interface as well as temporary or permanent elevated pacing thresholds. Follow these precautions when using external defibrillation on a patient with an implanted cardiac device:

- Position defibrillation paddles as far from the implanted device as possible (minimum of 13 cm (5 in)), and perpendicular to the implanted device-lead system.
- Use the lowest clinically appropriate energy output.

High-energy radiation – High radiation sources such as cobalt 60 or gamma radiation should not be directed at the implanted device. If a patient requires radiation therapy in the vicinity of the implanted device, place lead shielding over the device to prevent radiation damage and confirm its function after treatment.

Lithotripsy – Lithotripsy may permanently damage the implanted device if it is at the focal point of the lithotripsy beam. If lithotripsy must be used, keep the implanted device at least 2.5 to 5.0 cm (1 to 2 in) from the focal point of the lithotripsy beam.

Magnetic resonance imaging (MRI) – Magnetic Resonance Imaging (MRI) should not be used on patients who have an implanted cardiac device because of the potential damage to the implanted device.

Radio frequency (RF) ablation – Radio frequency ablation procedure in a patient with an implanted cardiac device could cause device malfunction or damage. RF ablation risks can be minimized by:

- Have a Medtronic programmer available for temporary pacing.
- Program tachyarrhythmia detection Off.
- Program a non-rate responsive, asynchronous pacing mode prior to the procedure.
- Avoid direct contact between the ablation catheter and the implanted lead or device.
- Position the ground plate so that the current pathway does not pass through or near the device system.
- Have defibrillation equipment available.

Therapeutic ultrasound – Exposure of the device to therapeutic ultrasound is not recommended as it may permanently damage the device. Damage to the device may affect therapy.

4.6 Home and occupational environments

Patients should be directed to avoid devices that generate strong electric or magnetic interference (EMI). EMI could cause inappropriate pacing inhibition, malfunction, or damage resulting in non-detection or delivery of unneeded therapy. Moving away from the interference source, or turning it off, usually allows the device to return to its normal mode of operation.

High voltage lines – High voltage power transmission lines could generate enough EMI to interfere with device operation if approached too closely.

Communication equipment – Communication equipment such as microwave transmitters, line power amplifiers, or high power amateur transmitters could generate enough EMI to interfere with device operation if approached too closely.

Commercial electrical equipment – Commercial electrical equipment such as arc welders, induction furnaces, or resistance welders could generate enough EMI to interfere with device operation if approached too closely.

Home appliances – Home appliances which are in good working order and properly grounded do not usually produce enough EMI to interfere with device operation. There are reports of device disturbances caused by electrical hand tools or electric razors used directly over the device implant site.

Static magnetic fields – Patients should avoid equipment or situations where they would be exposed to static magnetic fields (greater than 10 gauss or 1 millitesla) magnetic fields since it could suspend detection. Examples of magnetic sources that could interfere with normal device operation include: stereo speakers, bingo wand, extractor wand, magnetic badges, or magnetic therapy products.

Electronic article surveillance (EAS) – Electronic Article Surveillance (EAS) equipment such as retail theft prevention systems may interact with the implanted device. Patients should be advised to walk directly through, and not to remain near an EAS system longer than is necessary.

Cellular phones – Hand-held cellular phones do not need any special precautions if you have a Medtronic AT500™ device. For portable and mobile cellular phones that transmit above 3 watts, keep the telephone antenna 12 in (30 cm) away from the implanted device.

Tips to keep these distances:

Medtronic AT500™ devices contain a filter that prevents most cellular phone transmissions from interacting with device operation. To further minimize the possibility of interaction, observe the following cautions:

- Hold the phone to the ear opposite the side of the implanted device.
- When carrying the phone, keep it in a location opposite the side of the implanted device. (When a cell phone is in the "listen" or "standby" mode, it can still send a signal.)

Table 1. Cellular Phone Transmission Technologies

Transmission technology	Frequency range (MHz)
Analog FM (Frequency Modulation)	824 - 849
Digital TDMA^a North American Standards TDMA - 11Hz NADC ^b TDMA - 50Hz PCSS ^c 1900	806 - 821 824 - 849 1850 - 1910
Digital TDMA International Standards GSM ^d DCS ^e 1800	880 - 915 1710 - 1785
Digital CDMA CDMA - DS ^f	824 - 849

^a Time Division Multiple Access
^b North American Digital Cellular
^c Personal Communication System
^d Global System for Mobile Communications
^e Digital Cellular System
^f Code Division Multiple Access - Direct Sequence

5 Adverse Events

5.1 Potential Adverse Events

Adverse events (in alphabetical order), including those reported in Table 2 and Table 4, associated with pacing systems may include, but are not limited to:

- Cardiac perforation
- Cardiac tamponade
- Death
- Erosion of device through the skin
- Hematoma/seroma
- Infection
- Improper operation caused by the electronic article surveillance systems
- Nerve and/or muscle stimulation
- Pacemaker syndrome
- Rejection phenomena (local tissue reaction, fibrotic tissue formation, pacemaker migration)
- Threshold elevation

5.2 Observed Adverse Events

Two clinical studies are used to demonstrate safety and efficacy of the Medtronic AT500™ DDDR Pacing System and they are as follows:

- ATTEST - Atrial Therapy Efficacy and Safety Trial
- ASPECT - Atrial Septal Pacing Efficacy Clinical Trial

5.2.1 ATTEST Observed Adverse Events

For the ATTEST clinical study, reference Table 2 for a summary of all adverse events.

Table 2. Summary of Adverse Events Reported - ATTEST

Adverse Event Type	Brady+AT/AF Patients		All Patients		Total
	Complications ^a	Observations ^a	Complications	Observations	
System/Procedure Related	45 (40 Pts)	218 (153 Pts)	57 (49 Pts)	263 (185 Pts)	320 (208 Pts)
Non-System/Procedure Related	188 (136 Pts)	1461 (334 Pts)	251 ^b (168 Pts)	1740 ^b (385 Pts)	1991 (399 Pts)
Total	233 (162 Pts)	1679 (341 Pts)	308 (198 Pts)	2003 (395 Pts)	2311 (413 Pts)

^a A complication is defined as an adverse event requiring invasive measures to correct; a therapy is considered invasive if it penetrates the skin, excluding the administration of parenteral fluids or drugs. An observation is defined as an adverse event that is resolved using only non-invasive measures.

^b Includes adverse events categorized as "Unknown."

Table 3 is a listing of the system/procedure related adverse events for the ATTEST study. Of the 2311 events reported, 320 were system/procedure related.

Table 3. ATTEST System/Procedure Related Adverse Event Listing

Primary Condition	Complications		Observations		Total	
	Events	Patients* (%)	Events	Patients* (%)	Events	Patients* (%)
Atrial Flutter/Fibrillation Paroxysmal	2	2 (0.5)	5	5 (1.2)	7	7 (1.6)
Atrial Flutter/Fibrillation Persistent	0	0 (0)	2	2 (0.5)	2	2 (0.5)
Atrial Tachycardia	0	0 (0)	2	2 (0.5)	2	2 (0.5)
Back Pain/ Discomfort	0	0 (0)	2	2 (0.5)	2	2 (0.5)
Cardiac Perforation (Ventricular)	1	1 (0.2)	0	0 (0)	1	1 (0.2)
Chest Pain- Angina	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Chest Pain - non-cardiac	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Congestive Heart Failure	0	0 (0)	3	3 (0.7)	3	3 (0.7)
Cross-talk (non-persistent)	0	0 (0)	2	2 (0.5)	2	2 (0.5)
Daily Atrial Lead Check	0	0 (0)	24	22 (5.2)	24	22 (5.2)
Dizziness	0	0 (0)	3	3 (0.7)	3	3 (0.7)
Drug Related	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Dyspnea/ Shortness of Breath	0	0 (0)	4	4 (0.9)	4	4 (0.9)
Elevated Pacing Thresholds Atrial	0	0 (0)	2	2 (0.5)	2	2 (0.5)
Elevated Pacing Thresholds Ventricle	2	1 (0.2)	3	3 (0.7)	5	4 (0.9)
Emotional Distress	0	0 (0)	3	3 (0.7)	3	3 (0.7)
Failure To Capture/Loss Of Capture Atrial	0	0 (0)	3	3 (0.7)	3	3 (0.7)
Failure To Capture/Loss Of Capture Ventricle	1	1 (0.2)	1	1 (0.2)	2	2 (0.5)
Far-Field R-Wave Sensing	3	3 (0.7)	9	8 (1.9)	12	11 (2.6)
Fatigue/tiredness	1	1 (0.2)	1	1 (0.2)	2	2 (0.5)
Headache	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Hypotension	0	0 (0)	2	2 (0.5)	2	2 (0.5)
Inadequate Lead Pacemaker connection	2	2 (0.5)	0	0 (0)	2	2 (0.5)
Inappropriate programming	0	0 (0)	5	5 (1.2)	5	5 (1.2)
Lead Dislodgment Atrial	18	17 (4.0)	0	0 (0)	18	17 (4.0)
Lead Dislodgment Ventricle	5	5 (1.2)	0	0 (0)	5	5 (1.2)

Table 3. ATTEST System/Procedure Related Adverse Event Listing (Continued)

Primary Condition	Complications		Observations		Total	
	Events	Patients* (%)	Events	Patients* (%)	Events	Patients* (%)
Lead Insertion/Route Problem	2	2 (0.5)	2	2 (0.5)	4	4 (0.9)
Lead Insulation Failure	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Loss Of Sensing Intermittent	1	1 (0.2)	8	8 (1.9)	9	9 (2.1)
Loss Of Sensing Permanent	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Migration of pulse generator	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Musculoskeletal pain	0	0 (0)	2	2 (0.5)	2	2 (0.5)
Nausea	1	1 (0.2)	2	2 (0.5)	3	3 (0.7)
Near Syncope	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Other Conditions	3	3 (0.7)	20	20 (4.7)	23	23 (5.4)
Other Oversensing	0	0 (0)	6	6 (1.4)	6	6 (1.4)
Pacemaker-Mediated Tachycardia	0	0 (0)	3	3 (0.7)	3	3 (0.7)
Pain at pocket site	0	0 (0)	45	40 (9.4)	45	40 (9.4)
Palpitations	0	0 (0)	14	13 (3.0)	14	13 (3.0)
Pericardial Effusion	4	4 (0.9)	5	5 (1.2)	9	9 (2.1)
Peripheral Edema	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Phrenic Nerve/Diaphragm Muscle Stimulation Atrial	0	0 (0)	4	4 (0.9)	4	4 (0.9)
Phrenic Nerve/Diaphragm Muscle Stimulation Ventricle	4	4 (0.9)	1	1 (0.2)	5	5 (1.2)
Pleural Effusion	0	0 (0)	4	4 (0.9)	4	4 (0.9)
Pneumonia	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Pneumothorax as Result of Implant Procedure	2	2 (0.5)	6	6 (1.4)	8	8 (1.9)
Pocket Hematoma	1	1 (0.2)	17	17 (4.0)	18	18 (4.2)
Pocket Infection	1	1 (0.2)	10	10 (2.3)	11	10 (2.3)
Pocket Seroma	0	0 (0)	4	4 (0.9)	4	4 (0.9)
Pocket Stimulation	0	0 (0)	3	3 (0.7)	3	3 (0.7)
Puncture of Subclavian artery	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Shoulder pain/ discomfort	0	0 (0)	2	2 (0.5)	2	2 (0.5)
Sleep problems	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Suspected pacemaker failure	1	1 (0.2)	5	4 (0.9)	6	5 (1.2)

Table 3. ATTEST System/Procedure Related Adverse Event Listing (Continued)

Primary Condition	Complications		Observations		Total	
	Events	Patients* (%)	Events	Patients* (%)	Events	Patients* (%)
Suspected Programmer Or Software Failure	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Swelling of pocket site	2	2(0.5)	7	7 (1.6)	9	9 (2.1)
Thrombosis	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Upper pacing rate too slow	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Upper respiratory symptom	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Ventricular Tachycardia Non-Sustained	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Ventricular tachycardia (Sustained)	0	0 (0)	1	1 (0.2)	1	1 (0.2)
Total	57	49 (11.5)	263	185 (43.3)	320	208 (48.7)

* Some patients had events in more than one category.

5.2.2 ATTEST VT/VF Observations

Ten sustained VT/VF episodes were reported in four patients. The investigator classification and adverse event committee review did not indicate that any of the VT/VF episodes were caused by prevention pacing or ATP therapies.

5.2.3 ATTEST Patient Discontinuations

Lost to Follow-up forms were received for 19 patients. Six patients requested withdrawal from the study. Two forms were submitted at the time of patient's death.

5.2.4 ATTEST Patients Requiring Device Explant

A total of eight patients required device explant during the study period. Two patients received replacement Medtronic AT500™; two patients were not re-implanted with a pulse generator. Two patients required replacement with an ICD as a result of inducible sustained ventricular tachycardia. One patient was implanted with a Medtronic Kappa pulse generator as a result of a random component failure in the Medtronic AT500™ and one patient was implanted with an InSync 8040 pacemaker.

5.2.5 ATTEST Patient Deaths

Over the course of the study, 43 patients expired. For these deaths, neither the investigator nor the Adverse Event Advisory Committee attributed the cause of death to the Medtronic AT500™ system. The causes of death were cardiac arrest (7), congestive heart failure (7), cardiopulmonary arrest (5), renal failure (3), myocardial infarction (3), pulmonary arrest (3), sepsis (2), cardiogenic shock (2), cardiomyopathy, ventricular arrhythmia, perforation of superior vena cava, aspiration pneumonitis, intracerebral hemorrhage, atherosclerotic heart disease, emphysema, brain cancer, leukemia, pneumonia, and one death of unknown cause.

5.2.6 ASPECT Observed Adverse Events

For the ASPECT clinical study, reference Table 4 for a summary of all adverse events.

Table 4. Summary of Adverse Events - ASPECT

Adverse Event Type	Septal (n=148)		Non-Septal (n=150)		Total
	Complications ^a	Observations ^a	Complications	Observations	
System/ Procedure-Related	21 (19 Pts)	68 (55 Pts)	23 (21 Pts)	66 (50 Pts)	178 (127 Pts)
Non-System/ Procedure Related	72 (56 Pts)	252 (106 Pts)	75 (54 Pts)	244 (112 Pts)	643 (235 Pts)
Total	93 (66 Pts)	320 (121 Pts)	98 (68 Pts)	310 (121 Pts)	821 (261 Pts)

^a A complication is defined as an adverse event requiring invasive measures to correct; a therapy is considered invasive if it penetrates the skin, excluding the administration of parenteral fluids or drugs. An observation is defined as an adverse event that is resolved using only non-invasive measures.

Table 5 lists the system/procedure related adverse events for the ASPECT study. Of the 821 events reported, 178 were system or procedure related.

Table 5. ASPECT System/Procedure Related Adverse Event Listing

Primary Condition	Complications		Observations		Total	
	Events	Patients ^a (%)	Events	Patients ^a (%)	Events	Patients ^a (%)
Allergic Reaction	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Anxiety	0	0 (0)	2	2 (0.67)	2	2 (0.67)
Atrial Flutter/Fibrillation Paroxysmal	1	1 (0.34)	16	15 (5.03)	17	16 (5.37)
Atrial Flutter/Fibrillation Persistent	0	0 (0)	2	2 (0.67)	2	2 (0.67)
Aware of Pacing System	0	0 (0)	3	3 (1.01)	3	3 (1.01)
Belching	0	0 (0)	2	1 (0.34)	2	1 (0.34)
Chest Muscle Stimulation	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Chest Pain - non-cardiac	0	0 (0)	3	3 (1.01)	3	3 (1.01)
Chronic Obstructive Pulmonary Disease	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Congestive Heart Failure	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Cough	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Daily Atrial Lead Check Failure	0	0 (0)	10	7 (2.35)	10	7 (2.35)
Delayed Ventricular Pace	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Deep Vein Thrombosis	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Dyspnea/Shortness of Breath	0	0 (0)	2	2 (0.67)	2	2 (0.67)

Table 5. ASPECT System/Procedure Related Adverse Event Listing (Continued)

Primary Condition	Complications		Observations		Total	
	Events	Patients* (%)	Events	Patients* (%)	Events	Patients* (%)
Edema	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Electromagnetic Interference Sensing	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Elevated Pacing Thresholds Atrial	0	0 (0)	3	3 (1.01)	3	3 (1.01)
Elevated Pacing Thresholds Ventricle	3	3 (1.01)	4	4 (1.34)	7	7 (2.35)
Endocarditis	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Failure To Capture/Loss Of Capture Atrial	1	1 (0.34)	1	1 (0.34)	2	2 (0.67)
Failure To Capture/Loss Of Capture Ventricle	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Failure To Position The Lead At The Atrial Septum	0	0 (0)	1	1 (0.34)	1	1 (0.34)
False Rejection of Episodes Due To FFRW Criterion	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Far-Field R-Wave Sensing	0	0 (0)	4	4 (1.34)	4	4 (1.34)
Fatigue/tiredness	0	0 (0)	2	2 (0.67)	2	2 (0.67)
Inappropriate Programming	0	0 (0)	3	3 (1.01)	3	3 (1.01)
Incision Problem	0	0 (0)	5	5 (1.68)	5	5 (1.68)
Insufficient Slack in Atrial and Ventricular Leads	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Lead Dislodgment Atrial	7	7 (2.35)	2	2 (0.67)	9	9 (3.02)
Lead Dislodgment Ventricle	6	6 (2.01)	0	0 (0)	6	6 (2.01)
Lead Insertion/Route Problem	0	0 (0)	3	3 (1.01)	3	3 (1.01)
Loss Of Sensing Intermittent	0	0 (0)	4	4 (1.34)	4	4 (1.34)
Migration of lead	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Muscular Stimulation	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Nausea	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Other Oversensing	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Pacemaker Syndrome	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Pacemaker-Conducted Atrial Tachyarrhythmia	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Pacemaker-Mediated Tachycardia	0	0 (0)	9	8 (2.68)	9	8 (2.68)

62

Table 5. ASPECT System/Procedure Related Adverse Event Listing (Continued)

Primary Condition	Complications		Observations		Total	
	Events	Patients* (%)	Events	Patients* (%)	Events	Patients* (%)
Pain	0	0 (0)	14	14 (4.70)	14	14 (4.70)
Palpitations	0	0 (0)	3	3 (1.01)	3	3 (1.01)
Patient Activator Malfunction	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Pericardial Effusion	2	2 (0.67)	0	0 (0)	2	2 (0.67)
Phrenic Nerve/Diaphragm Muscle Stimulation Atrial	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Phrenic Nerve/Diaphragm Muscle Stimulation Ventricle	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Pneumothorax As Result Of The Implant Procedure	5	5 (1.68)	0	0 (0)	5	5 (1.68)
Pocket Hematoma	3	3 (1.01)	12	12 (4.03)	15	15 (5.03)
Pocket Infection	1	1 (0.34)	2	2 (0.67)	3	3 (1.01)
Pocket Site Opened	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Presyncope	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Skin Rash	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Stroke/CVA/TIA	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Subclavian Vein Perforation	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Suspected Lead Conductor Fracture Ventricle	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Suspected Programmer Or Software Failure	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Swelling Of Pocket Site	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Syncope	1	1 (0.34)	1	1 (0.34)	2	2 (0.67)
Thrombosis	0	0 (0)	1	1 (0.34)	1	1 (0.34)
Thrombosis Formation At Lead Ventricle	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Ventricular Fibrillation	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Ventricular Tachycardia Non-Sustained	1	1 (0.34)	0	0 (0)	1	1 (0.34)
Total	44	40 (13.40)	134	105 (35.20)	178	127 (42.60)

^a Some patients had events in more than one category.

5.2.7 ASPECT VT/VF Observations

Three sustained VT/VF episodes were reported in three patients. The investigator classification and adverse event committee review did not indicate that any of the VT/VF episodes were caused by prevention pacing or ATP therapies.

5.2.8 ASPECT Patient Discontinuations

Six patients requested withdrawal from the study. Four of them were never implanted with an Medtronic AT500™ and requested withdrawal. Two patients in Europe requested withdrawal after refusing to come to the investigator for follow-up visits.

5.2.9 ASPECT Patients Requiring Device Explant

Over the course of the study, eleven devices were explanted for reasons including worsening of congestive heart failure (five patients), ventricular fibrillation, MAZE procedure, endocarditis, pericardial effusion, and infection (two patients). Two devices were replaced with Medtronic AT500™ devices. Two devices were not replaced. Five devices were replaced with biventricular pacing devices, one device was replaced with an ICD, and one device was replaced with a Medtronic Kappa pulse generator.

5.2.10 ASPECT Patient Deaths

There were 17 patient deaths recorded in the study; all but one were determined to be non-system related by the investigator and the Adverse Event Advisory Committee. For one death it was unknown if it was related to the system since the patient, whose cause of death was congestive heart failure, was cremated before an explant or autopsy could be performed. Causes of death included congestive heart failure (4 patients), cancer (2 patients), cerebral vascular accident, myocardial infarction, coronary artery disease, cardiomegaly, respiratory failure, anoxic encephalopathy, acute heart failure, cardiac cachexy, cardiopulmonary arrest, cardiac arrhythmia and one death of unknown cause.

6 CLINICAL STUDY

Two clinical studies are used to demonstrate safety and efficacy of the Medtronic AT500™ DDDR Pacing System and they are as follows:

- ATTEST - Atrial Therapy Efficacy and Safety Trial
- ASPECT - Atrial Septal Pacing Efficacy Clinical Trial

6.1 Methods

Reference Table 6 for additional information.

Table 6. Overview of Clinical Studies

Study	Cohort	No. of Patients Enrolled	Cumulative No. of Device Months	Average No. of Device Months/Patient	No. of Implanting Centers	First Implant Date	Data Cut-off Date
ATTEST	Brady +AT/AF	370	6447	17.4	28	18 Oct 1999	26 April 2002
	Other Brady	57	1113	19.5			
ASPECT	Brady +AT/AF	298	5330	18.1	37	01 Sept 1999	26 April 2002

6.1.1 ATTEST Clinical Study

The ATTEST clinical study was a multi-center (28 implanting centers worldwide), prospective, randomized, parallel group, two-sample, single-blinded design performed to characterize the safety and effectiveness of the Medtronic AT500™ DDDR pacing system. Patients with or without a history of atrial tachyarrhythmias (AT/AF) were enrolled in the study. The location for placement of the atrial lead was left to the discretion of the investigator for patients indicated for a dual-chamber pacemaker. Reference Figure 1 for a description of the clinical study design.

To evaluate effectiveness of the atrial prevention (Atrial Preference Pacing (APP), Atrial Rate Stabilization (ARS) and Post Mode Switch Overdrive Pacing (PMOP)) and termination therapies (Atrial Antitachycardia Pacing (ATP)), all patients were stratified based on the presence or absence of documented history of AT/AF at enrollment. Patients with a documented history of AT/AF were categorized as Brady +AT/AF, and the patients without a documented history of AT/AF were categorized as Other Brady.

Patients were randomized to having prevention and termination therapies either all ON or all OFF at the one-month follow-up. A three-month evaluation period followed the randomization. Upon completion of the four-month follow-up visit, the protocol allowed the Medtronic AT500™ to be programmed according to the physician's preference.




Figure 1. ATTEST Clinical Study Design

6.1.2 ATTEST - Patient Assessment

Patients enrolled into the study represented a general dual chamber pacing population, as specified by the ACC/AHA guidelines for pacing indications. A total of 427 patients were enrolled and 424 were implanted. Of these patients, 370 were enrolled in the Brady +AT/AF group and the remaining 57 were enrolled in the Other Brady group. Three patients were not implanted with an Medtronic AT500™. Ventricular lead placement was not possible for two patients; one expired as a result of complications during the Medtronic AT500™ implant procedure prior to implantation of the device.

Primary Objectives

- To establish the safety of the Medtronic AT500™ system as demonstrated by freedom from system/procedure related complications at three months post-implant.
- Two measures of effectiveness of AT/AF prevention and termination therapies were evaluated.
 - Demonstration of the effectiveness of the prevention and termination therapies in reducing the frequency of spontaneous AT/AF episodes by 30%.
 - Demonstration of the effectiveness of the Medtronic AT500™ prevention and termination therapies in reducing the burden of spontaneous AT/AF episodes by 30%.

Secondary Objectives

- To estimate the accuracy (positive predictive value) of the atrial tachyarrhythmia detection algorithm in classification of atrial tachyarrhythmias (AT/AF).
- To characterize the effectiveness of ATP in terminating spontaneous AT/AF episodes.
- To characterize the potential reduction of frequency and burden in patients who had no documented history of atrial tachyarrhythmias at enrollment. To demonstrate the impact of the Medtronic AT500™ system on patients' quality of life as measured by the SF-36 Health Survey and Symptom Checklist.
- To characterize the pacing and sensing performance of the Medtronic AT500™ system using the Medtronic DR180 digital Holter recorder.
- To characterize the effect of prevention and termination therapies on the frequency of symptomatic episodes of atrial tachyarrhythmias (AT/AF).

6.1.3 ATTEST - Demographic Data

The mean age of the total population was 70.0 years; the mean age of the Brady+AT/AF population was 69.9 years. Male patients comprised 54.6% of the Brady+AT/AF group and 54.3% of all patients were male.

Table 7. ATTEST-Patient Demographics

Patient Characteristics	Brady+AT/AF (N=370)	Other Brady (N=57)	All (N=427)
Gender (N%)			
Male	202(54.6%)	30(52.6%)	232(54.3%)
Female	168(45.4%)	27(47.4%)	195(45.7%)
Age (years)			
Mean	69.9	70.5	70.0
Range	10.0 - 98.0	13.0 - 90.0	10.0 - 98.0
Standard deviation	12.9	16.1	13.4
Primary Indication (mutually exclusive, N%)			
Acquired AV Block	42(11.4%)	27(47.4%)	69(16.2%)
Chronic Bi/tri-fascicular Block	2(0.5%)	2(3.5%)	4(0.9%)
AV Block with Acute MI	2(0.5%)	-	2(0.5%)
Sinus Node Dysfunction	267(72.2%)	24(42.1%)	291(68.1%)
Prevention and Termination of Tachy	45(12.2%)	1(1.8%)	46(10.8%)
Other	12(3.2%)	3(5.3%)	15(3.5%)

6.1.4 ATTEST - Data Analysis and Results

Accumulating 7561 device months of experience, the performance of the Medtronic AT500™ DDDR pacing system was found to meet or exceed all safety objectives as shown in Table 8. The rate of complications was found to be similar to that observed in Medtronic studies of pacemakers that are commercially available.

Table 8. Results of Primary Objectives - ATTEST

Primary Objectives:	Results:
Safety (n=427) Hypothesis: 3 Month System / Procedure-Related Complication-Free Survival Greater than 80% - All Patients	40 patients experienced their first system/procedure-related complication through 3 months of follow-up Complication Free Survival Probability: 90.3% 95% Lower Confidence Bound: 87.7% (> 80%)
Effectiveness: AT/AF Frequency Reduction, AT/AF Burden Reduction Hypothesis: The frequency of AT/AF episodes with prevention and termination ON will be at least 30% less than the frequency with prevention and termination OFF.	For patients in the efficacy cohort of the Brady+AT/AF group, the median frequency in the ON arm was 0.043 episodes/day and in the OFF arm it was 0.039 episodes/day. The median burden in the ON arm was 0.136 hours/day and in the OFF arm it was 0.037 hours/day. The difference between arms was not statistically significant for either frequency or burden.

Table 9. Results of Secondary Objectives - ATTEST

Secondary Objectives:	Results:
Accuracy (positive predictive value) of appropriately detecting atrial tachyarrhythmias	According to investigator classifications, the positive predictive value for detection of atrial arrhythmias was 98%.
Effectiveness of terminating spontaneous AT/AF episodes	ATP therapies effectively terminated 53.3% of all treated episodes base on crude estimates and 40.8% when adjusted using the Generalized Estimating Equations methodology.
Reduction of frequency and burden in patients who had no history of atrial tachyarrhythmias at enrollment	No statistically significant difference was found in frequency and burden comparisons between treatment groups in the Other Brady patient group.
Patients' quality of life as measured by the SF-36 Health Survey and Symptom Checklist	As measured by the SF-36 and the Symptom Checklist, there was no statistically significant difference in quality of life between the ON and OFF groups at Baseline and 4-months. However, quality of life of all patients improved from Baseline to 4-months, and at 4 months patients in both groups scored in the normal range for the age-matched population at large. ^a
Pacing and sensing performance using the DR180 digital Holter recorder	One hundred five (105) Holter recordings were reviewed from 66 patients to characterize pacing and sensing performance of the AT500. The Holter recordings confirm that the AT500 operated as expected.
Frequency of symptomatic AT/AF episodes	The ON group had a frequency of 0.057 symptomatic episodes per day, while the OFF group had a frequency of 0.064 symptomatic episodes per day. There was no statistically significant difference in frequency of symptomatic episodes between ON and OFF treatment groups.

^a Ware JE, Snow KK, Kosinski M et al. *SF-36 Health Survey Manual and Interpretation Guide*. QualityMetric Incorporated, Lincoln, RI, 2000, pg 7:15.

6.1.5 ATTEST - Device Failures and Replacement

There was one device failure reported as part of the ATTEST Clinical study. This device was explanted as a result of a ventricle sense failure. The device was returned to Medtronic for further analysis. Analyses indicated that this was a random component failure caused by a resistive leakage in the pre-amp of the L292 IC.

6.1.6 ASPECT Clinical Study

The ASPECT clinical study was a multi-center (37 implanting centers worldwide), prospective, randomized, single-blinded, cross-over design performed to investigate the safety and efficacy of the Medtronic AT500™ DDDRP pacing system and its atrial arrhythmia prevention pacing features with specific atrial lead placement. Patients were candidates for a standard pacemaker and had a history of symptomatic atrial tachyarrhythmia. Lead placement sites included septal and non-septal atrial pacing sites.

This study was a prospective evaluation of the following features of the Medtronic AT500™ DDDRP Pacing System: Atrial Preference Pacing (APP), Atrial Rate Stabilization (ARS) and Post Mode Switch Overdrive Pacing (PMOP). Patient data was collected at implant, pre-discharge, one month, four month, and seven months post implant.

At implant, patients were randomized to either a septal or non-septal atrial lead site placement. A second randomization was performed for prevention pacing features (APP, ARS, PMOP) ON-OFF vs. OFF-OFF crossover periods at the one-month follow-up. The crossover period was 3 months, with the first 2 weeks of each crossover period considered a stabilization period to account for atrial remodeling effects. Data from the 2-week stabilization period was not utilized for the efficacy objectives. Data was collected at the end of each crossover period of 3 months (See Figure 2).




Figure 2. ASPECT Clinical Study Design

6.1.7 ASPECT - Patient Assessment

Patients enrolled into the study represented a general dual chamber pacing population, as specified by the ACC/AHA guidelines for pacing indications. A total of 298 patients were enrolled and 294 were implanted. Of the four not implanted, one patient was discovered to be in permanent AF at implant, one patient was found to have 1:1 conducted sinus tachycardia at implant, one patient had high atrial thresholds at implant, and one patient could not be transferred to the study center after enrollment.

Primary Objectives

- To establish the safety of the Medtronic AT500™ system as demonstrated by freedom from system/procedure related complications at three months post-implant.
- To establish the safety of atrial leads when used in the septal pacing site as demonstrated by freedom from atrial lead related adverse events at three months post-implant.
- To demonstrate that the prevention pacing features reduce atrial tachyarrhythmia frequency by at least 30% in at least 50% of patients when used in conjunction with an atrial septal pacing site.
- To demonstrate that the proportion of patients with at least a 30% reduction in frequency in the septal site (prevention pacing features ON vs. OFF) will be greater than the proportion in the non-septal site (prevention pacing features ON vs. OFF).

Secondary Objectives

- To observe the performance of the prevention pacing features during Holter monitoring.
- To characterize the electrical performance (pulse width thresholds at 2.0V, sensing thresholds, and lead impedance) of atrial leads over time.
- To characterize the effect that the prevention pacing features have on atrial tachyarrhythmia burden in the septal and non-septal atrial pacing sites.
- To characterize the effect the prevention pacing features have on patient quality of life in the septal and non-septal atrial pacing sites.

- To characterize the effect that the prevention pacing features have on the frequency of symptomatic episodes of atrial tachyarrhythmias in the septal and non-septal atrial pacing sites.
- To characterize the effect that the prevention pacing features have on the frequency of premature atrial contractions in the septal and non-septal atrial pacing sites.
- To characterize the placement of an atrial lead in the septal pacing site.

6.1.8 ASPECT - Demographic Data

Information regarding patient demographics and cardiovascular history is presented in Table 10. The mean age of the 298 enrolled patients was 69.6 years. There were 182 males (61.1%) and 116 females (38.9%) in the ASPECT study. The patients' indications for pacemaker implants are also shown in Table 10.

Table 10. ASPECT-Patient Demographics

Patient Characteristics	Septal (N=148)	Non-Septal (N=150)	Total (N=298)
Gender (N%)			
Male	91(61.5%)	91(60.7%)	182(61.1%)
Female	57(38.5%)	59(39.3%)	116(38.9%)
Age (years)			
Mean	68.6	70.7	69.6
Range	42.6 - 87.5	45.4 - 88.5	42.6 - 88.5
Standard deviation	10.1	9.5	9.9
Primary Indication (N%) (mutually exclusive)			
Acquired AV Block	18(12.2%)	18(12.0%)	36(12.1%)
Chronic Bi/Tri-fascicular Block	3(2.0%)	2(1.3%)	5(1.7%)
Sinus Node Dysfunction	104(70.3%)	103(68.7%)	207(69.5%)
Other	23(15.5%)	27(18.0%)	50(16.8%)

6.1.9 ASPECT - Data Analysis and Results

Accumulating 5330.3 device months of experience, the performance of the Medtronic AT500™ was found to meet or exceed all safety objectives as shown in Table 11. The rate of complications was found to be similar to that observed in Medtronic studies of pacemakers that are commercially available.

Table 11. Results of Primary Objectives - ASPECT

Primary Objectives:	Results:
<p>Safety (n=298) Hypothesis: 3 Month System / Procedure-Related Complication-Free Survival Greater than 80%.</p>	<p>37 patients experienced their first system/procedure-related complication through 3 months of follow-up Complication Free Survival Probability at three months: 87.4 % 95% Lower Confidence Bound: 84.3% (> 80 %)</p>
<p>Safety of atrial leads when used in septal sites (n=148 septal, 150 non-septal) Hypothesis: Difference in 3 Month Atrial Lead-Related Event-Free Survival of Septal and Non-Septal Leads is < 10%.</p>	<p>11 septal patients and 7 non-septal patients experienced their first atrial lead related adverse event through three months of follow-up. Event Free Survival Probability (Septal): 92.5% 95% Confidence Interval (Septal): (88.3%, 96.8%) Event Free Survival Probability (Non-septal): 95.3% 95% Confidence Interval (Non-septal): (92.0%, 98.8%) 95% Upper Confidence Bound (difference in survival rate): 7.5% (< 10 %)</p>
<p>Effectiveness: AT/AF frequency reduction with an atrial septal pacing site. Hypothesis: The proportion of patients with a significant (at least 30%) reduction in frequency of AT/AF episodes with prevention pacing ON vs. OFF must be at least 50%.</p>	<p>In the atrial septal patients in the efficacy cohort, 30.7% of patients had 30% or greater reduction of frequency in the ON period as compared to the OFF period of the study with a one-sided 95% lower confidence bound of 21.9%. The proportion of septal patients with 30% or greater reduction in frequency was not at least 50% (the a priori objective performance criterion).</p>
<p>Effectiveness: AT/AF frequency reduction for septal compared to non-septal patients Hypothesis: The proportion of patients with a significant (at least 30%) reduction in frequency of AT/AF episodes in the septal site (prevention pacing features ON vs. OFF) will be greater than the proportion in the non-septal site (prevention pacing features ON vs. OFF).</p>	<p>The proportion of patients with non-septal atrial leads who had 30% or greater reduction in frequency in the ON period as compared to the OFF period was 32.2%, and the proportion of patients with septal atrial leads who had a 30% or greater frequency reduction was 30.7%. The proportion of septal patients with a frequency reduction of at least 30% was not significantly greater than the percent of non-septal patients with at least 30% frequency reduction.</p>

Table 12. Results of Secondary Objectives - ASPECT

Secondary Objectives:	Results:
Observation of the performance of prevention pacing features during Holter monitoring.	At the one-month follow-up, 20 patients with septal atrial lead implants and 22 patients with non-septal atrial lead implants were Holter monitored for 24 hours with the prevention features ON. Analysis of the Holter recordings showed that all evaluated features operated as expected and there were no differences noted between septal and non-septal patients.
Electrical performance of the atrial leads.	Pulse width thresholds, sensing thresholds, and lead impedance were measured for both septal and non-septal patients from implant through seven months. The electrical performance of the leads was not significantly different in the septal and non-septal groups.
Atrial tachyarrhythmia burden in septal and non-septal pacing sites.	For patients in the efficacy cohort, in the septal site, the median difference in burden between the ON and OFF periods was not significantly different from zero. In the non-septal site, the median difference in burden was also not significantly different from zero. The change in burden for the septal group was not significantly different from the corresponding change in the non-septal group.
Quality of Life in septal and non-septal pacing sites.	For patients in the efficacy cohort, as measured by the SF-36 Health Survey, patients in both the septal and non-septal arms had no significant change in quality of life scores for prevention pacing features ON vs. OFF. Patients scored in the normal range for the age-matched population at large during both the ON and OFF crossover periods. ⁹ Similarly, the Symptom Checklist measurements had no significant difference in the number of symptoms, symptom frequency, or symptom severity for patients in both the septal and non-septal arms with prevention pacing features ON versus OFF.
Frequency of symptomatic episodes of atrial tachyarrhythmias in septal and non-septal pacing sites.	For patients in the efficacy cohort, in the septal site, the mean difference in symptomatic episodes between the ON and OFF periods was -1.1 episodes/month (1.4 episodes/month ON versus 2.5 episodes/month OFF), which is significantly different from zero (p=0.013); in the non-septal site, the mean difference in symptomatic episodes was not significantly different from zero.
Frequency of premature atrial contractions in septal and non-septal atrial pacing sites.	For patients that were in the efficacy cohort, in the septal site, the median difference in PACs for ON - OFF was -202.5 PACs/day, which was not significantly different from zero (p=0.073). In the non-septal site, the median difference in PACs for ON - OFF was -273.3 PACs/day, which was significantly different from zero (p<0.001). The change in PACs for the septal group was not significantly different from the corresponding change in the non-septal group.

72

Table 12. Results of Secondary Objectives - ASPECT (Continued)

Secondary Objectives:	Results:
Atrial lead placement.	There were 148 patients randomized to the septal atrial lead site. Of these, 136 (91.9%) were placed in the septal site. Of the 12 patients who were not placed in the septal site as randomized, four were never implanted with an Medtronic AT500™ system, four were mechanically unable to reach and fixate on the septum (failure to implant the Medtronic AT500™ system was not related to septal lead randomization), two were unable to find acceptable thresholds on the septum, one discovered after implant that the lead was not on the septum, and one abandoned septal positioning for a medical reason. In addition, after implant, two patients with septal lead placement had lead dislodgements resulting in a repositioning of the lead to a non-septal position because the physician was mechanically unable to reach and fixate on the septum. Of the 150 leads randomized to the non-septal site, 150 (100%) were placed as randomized.

^a Ware JE, Snow KK, Kosinski M et al. *SF-36 Health Survey Manual and Interpretation Guide*. QualityMetric Incorporated, Lincoln, RI, 2000, pg 7:15.

6.1.10 ASPECT - Prevention Pacing and Percentage Atrial Pacing

The prevention pacing features (APP, ARS and PMOP) were observed to increase the percentage of atrial pacing while minimizing increase in atrial rate. The atrial pacing percentage increased from 69.0% with prevention pacing features OFF to 95.5% with prevention pacing features ON. The average atrial rate increased only slightly, from 72 ppm with prevention pacing features OFF to 77 ppm with prevention pacing features ON.

6.1.11 ASPECT - Reduction in Symptomatic Episode Burden

The prevention pacing features were observed to reduce the burden of symptomatic episodes in patients with an atrial septal lead placement. Burden was defined, post hoc, as the number of symptomatic days divided by the number of total days of follow up. A symptomatic day was a day in which a symptomatic episode was reported by the patient. For all patients with atrial septal lead placement (N=125), the burden of symptomatic episodes was 4.48% when the prevention features were OFF compared to 2.76% when the prevention features were ON, for a 38.4% reduction (p = 0.0043).

6.1.12 ASPECT - Device Failures and Replacement

There were no device failures reported as part of the ASPECT Clinical study.

6.2 Compassionate Use Device Clinical Experience

To date, there have also been 41 compassionate uses implants of the Medtronic AT500™ system. The compassionate use experience has a similar safety profile to the ATTEST and ASPECT clinical studies.

7 Physician and Patient Information

Documentation for the Medtronic AT500™ DDDR Pacing System includes the following:

- *Product Information Manual*
Implanter information, summary specifications and feature descriptions (shipped with device).
- *System Reference Guide*
Comprehensive reference on system design, operations, programming, and clinical use (shipped with software)
- *9968 Software Supplement*
Updates to series 5.0 for the 2090 programmer. The series 2.2 is used with the 9790/C programmers. Medtronic AT500™ software is Model 9968.
- *For Your AT500™ Pacemaker*
Information for the patient, patient's family, and other interested people (shipped with device).

To obtain additional copies of these documents, contact your Medtronic representative.

7.1 Device Registration

Verify device operating characteristics at the time of implantation and record them in the patient file.

Complete the Device Registration Form and return it to Medtronic as it provides necessary information for warranty purposes and patient tracking.

7.2 Patient Counseling

Physicians should consider the following points in counseling the patient about this implanted device:

- Encourage the patient to use an identification card (issued by Medtronic) and/or identification bracelets documenting the implanted device system.
- Discuss information in the patient manual so that the patient is fully familiar with the operation of the implanted device.
- Advise the patient how to obtain additional copies of the patient manual.

8 Explanation of Symbols




Symbol	Explanation
	Manufacturing date
	Use by
	Serial number
	Lot number
	Sterilization: Ethylene Oxide Gas
	Non-reusable
	Storage temperature
	Dangerous voltage
	Open here
	See accompanying documents
! USA	Caution: United States law restricts this device to sale by or on order of a physician.

MEDTRONIC CONFIDENTIAL

ImplTR1 06/00
UC199804968 EN Market Release
Clean Copy

182320.PPI.book Page 25 Monday, March 24, 2003 7:29 AM


IMPLNTEN.BCV



182320001



Rev A



MEDTRONIC CONFIDENTIAL

IMPLNTEN.BCV

ImpltR1 06/00
UC199804968 EN Market Release
Clean Copy

182320.PPI.book Page 26 Monday, March 24, 2003 7:29 AM



Medtronic

When Life Depends on Medical Technology

Europe

Europe/Africa/Middle East Headquarters

Medtronic Europe Sàrl.
Route du Molliat
1131 Tolochenaz
Switzerland
Internet: www.medtronic.co.uk
Tel. 41-21-802-7000
Fax 41-21-802-7900

Medtronic E.C. Authorized Representative

Medtronic B.V.
Earl Bakkenstraat 10
6422 PJ Heerlen
The Netherlands
Tel. 31-45-566-8000
Fax 31-45-566-8668

Asia-Pacific

Japan

Medtronic Japan
Solid Square West Tower 6F,
580 Horikawa-cho, Saiwai-ku,
Kawasaki, Kanagawa 210-0913
Japan
Tel. 81-44-540-6112
Fax 81-44-540-6200

Australia

Medtronic Australasia Pty. Ltd.
Unit 4/446 Victoria Road
Gladesville NSW 2111
Australia
Tel. 61-2-9879-5999
Fax 61-2-9879-5100

Asia

Medtronic International Ltd.
Suite 1602 16/F, Manulife Plaza
The Lee Gardens, 33 Hysan Avenue
Causeway Bay
Hong Kong
Tel. 852-2891-4068
Fax 852-2591-0313

Americas

Latin America

Medtronic, Inc.
600 West Hillsboro Boulevard
Suite 500
Deerfield Beach, FL 33441
USA
Tel. 954-428-8556
Fax 954-428-8984

Canada

Medtronic of Canada Ltd.
6733 Kitimat Road
Mississauga, Ontario L5N 1W3
Canada
Tel. 905-826-6020
Fax 905-826-6620
Toll-free in Canada: 1-800-268-5346

United States

World Headquarters
Medtronic, Inc.
710 Medtronic Parkway NE
Minneapolis, MN 55432-5604
USA
Internet: www.medtronic.com
Tel. 763-514-4000
Fax 763-514-4879

Medtronic USA, Inc.

Toll-free in the USA:
1-800-505-4636
(24-hour consultation for physicians and
medical professionals)



* 1 8 2 3 2 0 0 1 *

© Medtronic, Inc. 2003
All Rights Reserved
UCX182320001 182320001
March 2003

182320001

Rev A

77